Trial
NCT04570631
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
—
Condition
Multiple Myeloma
Intervention
Eftozanermin alfa
Why stopped
Strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16